Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.
The FDA approval, based on the successful completion of two pivotal clinical trials, made teprotumumab-trbw (Tepezza, Horizon Therapeutics) the only approved medical therapy for thyroid eye disease. The rollout was followed shortly by the onset of the COVID-19 pandemic. Despite the inherent challenges associated with any drug rollout during a crisis, physician